Literature DB >> 19349514

Impact of human serum albumin on oritavancin in vitro activity against enterococci.

Geoffrey A McKay1, Sylvain Beaulieu, Ingrid Sarmiento, Francis F Arhin, Thomas R Parr, Gregory Moeck.   

Abstract

Oritavancin is a lipoglycopeptide with activity against gram-positive pathogens including vancomycin-resistant enterococci. The impact of human serum albumin (HSA) on oritavancin activity against enterococci was compared to those of vancomycin, daptomycin, teicoplanin, and linezolid in vitro using MIC and time-kill methods. Oritavancin MICs increased between 0- and 8-fold in the presence of HSA. In time-kill assays with HSA, oritavancin retained activity, killing or inhibiting enterococci more rapidly than did comparators when peak concentrations were simulated.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19349514      PMCID： PMC2687190          DOI： 10.1128/AAC.00197-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose.

Authors:  Gerald J Fetterly; Christine M Ong; Sujata M Bhavnani; Jeffrey S Loutit; Steven B Porter; Lisa G Morello; Paul G Ambrose; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

2.  Evaluation of daptomycin, telavancin, teicoplanin, and vancomycin activity in the presence of albumin or serum.

Authors:  Brian T Tsuji; Steven N Leonard; Paul R Rhomberg; Ronald N Jones; Michael J Rybak
Journal:  Diagn Microbiol Infect Dis       Date:  2008-01-14       Impact factor: 2.803

3.  Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus.

Authors:  G G Zhanel; I D Kirkpatrick; D J Hoban; A M Kabani; J A Karlowsky
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

Review 4.  Glycopeptide antibiotics: from conventional molecules to new derivatives.

Authors:  Françoise Van Bambeke; Yves Van Laethem; Patrice Courvalin; Paul M Tulkens
Journal:  Drugs       Date:  2004       Impact factor: 9.546

5.  Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.

Authors:  Francis F Arhin; Ingrid Sarmiento; Adam Belley; Geoffrey A McKay; Deborah C Draghi; Parveen Grover; Daniel F Sahm; Thomas R Parr; Gregory Moeck
Journal:  Antimicrob Agents Chemother       Date:  2008-02-25       Impact factor: 5.191

6.  Impact of plasma protein binding on antimicrobial activity using time-killing curves.

Authors:  M A Zeitlinger; R Sauermann; F Traunmüller; A Georgopoulos; M Müller; C Joukhadar
Journal:  J Antimicrob Chemother       Date:  2004-10-07       Impact factor: 5.790

7.  Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin.

Authors:  E M Bailey; M J Rybak; G W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191
  7 in total
  7 in total

1.  Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections.

Authors:  Cesar A Arias; Rodrigo E Mendes; Matthew G Stilwell; Ronald N Jones; Barbara E Murray
Journal:  Clin Infect Dis       Date:  2012-04       Impact factor: 9.079

Review 2.  Seventy-Five Years of Research on Protein Binding.

Authors:  Axel Dalhoff
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

3.  An aryl isonitrile compound with an improved physicochemical profile that is effective in two mouse models of multidrug-resistant Staphylococcus aureus infection.

Authors:  Haroon Mohammad; Kwaku Kyei-Baffour; Nader S Abutaleb; Mingji Dai; Mohamed N Seleem
Journal:  J Glob Antimicrob Resist       Date:  2019-04-30       Impact factor: 4.035

4.  Effect of ester to amide or N-methylamide substitution on bacterial membrane depolarization and antibacterial activity of novel cyclic lipopeptides.

Authors:  Nina Bionda; Renee M Fleeman; Lindsey N Shaw; Predrag Cudic
Journal:  ChemMedChem       Date:  2013-06-18       Impact factor: 3.466

5.  Bacteriological profiling of diphenylureas as a novel class of antibiotics against methicillin-resistant Staphylococcus aureus.

Authors:  Haroon Mohammad; Waleed Younis; Hany G Ezzat; Christine E Peters; Ahmed AbdelKhalek; Bruce Cooper; Kit Pogliano; Joe Pogliano; Abdelrahman S Mayhoub; Mohamed N Seleem
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

6.  Current and future options for treating complicated skin and soft tissue infections: focus on fluoroquinolones and long-acting lipoglycopeptide antibiotics.

Authors:  Christian Eckmann; Paul M Tulkens
Journal:  J Antimicrob Chemother       Date:  2021-11-22       Impact factor: 5.790

7.  Targeting Multidrug-resistant Staphylococci with an anti-rpoA Peptide Nucleic Acid Conjugated to the HIV-1 TAT Cell Penetrating Peptide.

Authors:  Mostafa Fn Abushahba; Haroon Mohammad; Mohamed N Seleem
Journal:  Mol Ther Nucleic Acids       Date:  2016-07-19       Impact factor: 10.183
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.